What is DotLab?
DotLab is at the forefront of women's healthcare technology, specializing in the development of DotEndo, a revolutionary non-invasive blood test for the diagnosis of active endometriosis. This advanced diagnostic tool analyzes specific blood biomarkers to detect the disease across all stages, irrespective of hormonal cycles or symptom presentation. By targeting both patients and clinicians, DotEndo aims to drastically reduce the diagnostic timeline, which historically averages over eleven years, thereby enabling earlier and more effective treatment strategies. The company's innovative approach addresses a critical unmet need in women's health, particularly for individuals experiencing unexplained infertility.
How much funding has DotLab raised?
DotLab has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2019): $10M with participation from CooperSurgical, TriplePoint Venture Growth BDC, Wilson Sonsini Goodrich & Rosati, and Luxor Capital Group
Key Investors in DotLab
CooperSurgical
CooperSurgical is a key participant in this funding round, contributing to DotLab's strategic growth in the women's health technology sector.
TriplePoint Venture Growth BDC
TriplePoint Venture Growth BDC, known for its focus on venture growth stage companies, provides crucial financial backing to innovative firms like DotLab.
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati, a prominent law firm, offers its expertise, likely in legal and corporate matters, supporting DotLab's strategic development.
What's next for DotLab?
With its recent major strategic investment, DotLab is poised for significant expansion and further development of its groundbreaking endometriosis diagnostic technology. The substantial capital infusion, part of a major enterprise-level funding initiative, will likely fuel advancements in clinical validation, market penetration, and the scaling of operations. This strategic financing signals strong investor confidence in DotLab's mission to revolutionize women's health diagnostics and improve patient outcomes by accelerating the diagnosis of endometriosis.
See full DotLab company page
